Page last updated: 2024-11-05

perflutren

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6432
CHEMBL ID1663
CHEBI ID31980
MeSH IDM0126329

Synonyms (87)

Synonym
perfluoropropane
propane, octafluoro-
octafluoropropane-lipid microsphere
PERFLUTREN-LIPID MICROSPHERE
dmp 115
definity
ym454
9048-46-8
fc 218 (refrigerant)
r 218
einecs 200-941-9
genetron 218
perflutren [usan]
pfc 218
un 2424
mrx-115
fs069
optison
hfc 218
un2424
DB00556
perflutren (jan/usan/inn)
definity (tn)
D01738
76-19-7
octafluorpropan
perflutren
oktafluorpropan
octafluoropropane
1,1,1,2,2,3,3,3-octafluoropropane
fc 218
freon 218
CHEBI:31980 ,
CHEMBL1663
dmp-115
fs-069
A838638
1,1,1,2,2,3,3,3-octakis(fluoranyl)propane
c3f8-gas
R218 ,
AKOS006228213
ec 200-941-9
ck0n3wh0sr ,
perflutren lipid microsphere
perflutren lipid microspheres
hsdb 8074
perflutren protein-type a microspheres injection
propane, 1,1,1,2,2,3,3,3-octafluoro-
perflutren [usan:inn:ban]
unii-ck0n3wh0sr
octafluoropropaneor refrigerant gas r 218
octafluoropropaneor refrigerant gas r 218 [un2424] [nonflammable gas]
FT-0631321
perfluoropropane [inci]
perflutren [vandf]
perflutren [jan]
perflutren [inn]
perflutren [ii]
perflutren [ema epar]
oxtafluoropropane [vandf]
perflutren [who-dd]
luminity
octafluoro-propane
octafluoropropane [vandf]
perfluoropropane [mi]
perflutren [mart.]
dmp115
perflutren [orange book]
propane,1,1,1,2,2,3,3,3-octafluoro-
c3f8
mrx 115
optison (salt/mix)
DTXSID9052503 ,
mfcd00039239
FT-0621948
Q412659
FS-6566
AMY6865
perflutren (mart.)
refrigerant gas r-218
perflutren (ii)
perflutrenum
definity rt
dtxcid3031076
perflutrene
perflutreno
oxtafluoropropane

Research Excerpts

Toxicity

Although our sample size is small, perflutren contrast agents appear to be safe and well tolerated in children. Our combined signal detection/evaluation analysis did not identify SDRs of novel adverse events or major cardiovascular events.

ExcerptReferenceRelevance
" However, toxic effects on the rabbit retina have been reported even for the lowest effective doses."( Ocular toxicity of daunomycin: effects of subdivided doses on the rabbit retina after vitreous gas compression.
Chen, EP; Hatchell, DL; Machemer, R; Steinhorst, UH, 1993
)
0.29
" According to the histological analysis, OFP at the concentrations of 300 and 30 g/m3 had a politrophic toxic effect."( [Octafluoropropane inhalation toxicity].
Anisimov, BV; Ivanova, SM; Markin, AA; Mikos, KN; Mukhamedieva, LN; Nikitin, EI,
)
0.13
"During macular hole surgery, indocyanine green (ICG) has access to the subretinal space and can lead to toxic and phototoxic damage of the retinal pigment epithelium (RPE)."( Modified technique for safer indocyanine-green-assisted peeling of the internal limiting membrane during vitrectomy for macular hole repair.
Belting, C; Cresti, F; Genovesi-Ebert, F; Rizzo, S; Vento, A, 2006
)
0.33
" Safety was determined evaluating vital signs, physical examination, ECG, and adverse events."( Safety of contrast-enhanced echocardiography within 24 h after acute myocardial infarction.
Bax, JJ; Holman, ER; Marsan, NA; Nucifora, G; Poldermans, D; Schalij, MJ; Schuijf, JD; Siebelink, HM; van Werkhoven, JM, 2008
)
0.35
"The purpose of this retrospective analysis was to define the incidence of severe adverse events after exposure to ultrasound contrast agents."( The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses.
Carson, L; Chaudhry, FA; Davidoff, R; Fane, L; Farrar, M; Gabriel, R; Grimm, RA; Herzog, CA; Irani, W; Lang, RM; Mulvagh, SL; Porter, TR; Taylor, R; Wei, K; Wilson, S; Zoghbi, WA, 2008
)
0.35
" The incidence of severe adverse reactions to ultrasound contrast agents is no greater, and may be lower, than that reported for contrast agents commonly used in other cardiac imaging tests."( The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses.
Carson, L; Chaudhry, FA; Davidoff, R; Fane, L; Farrar, M; Gabriel, R; Grimm, RA; Herzog, CA; Irani, W; Lang, RM; Mulvagh, SL; Porter, TR; Taylor, R; Wei, K; Wilson, S; Zoghbi, WA, 2008
)
0.35
"The combined use of intracameral gas and compression sutures in corneal hydrops with stromal clefts is an effective and safe modality of treatment."( Efficacy and safety of intracameral perfluoropropane (C3F8) tamponade and compression sutures for the management of acute corneal hydrops.
Karkhanis, A; Raghavan, A; Rajaraman, R; Singh, S, 2009
)
0.35
" Immediate contrast agent-related adverse effects were also reported."( Safety of contrast agent use during stress echocardiography: a 4-year experience from a single-center cohort study of 26,774 patients.
Abdelmoneim, SS; Bernier, M; Dhoble, A; Hagen, ME; McCully, RB; Moir, S; Mulvagh, SL; Ness, SA; Pellikka, PA; Scott, CG, 2009
)
0.35
" Contrast agent-related adverse effects occurred in <1% of patients."( Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study.
Abdelmoneim, SS; Bernier, M; Dhoble, A; Hagen, ME; McCully, RB; Moir, S; Mulvagh, SL; Ness, SA; Pellikka, PA; Scott, CG, 2010
)
0.36
"RVSP had no impact on predisposition to adverse outcomes in patients undergoing contrast SE in the population studied."( Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study.
Abdelmoneim, SS; Bernier, M; Dhoble, A; Hagen, ME; McCully, RB; Moir, S; Mulvagh, SL; Ness, SA; Pellikka, PA; Scott, CG, 2010
)
0.36
"Although our sample size is small, perflutren contrast agents appear to be safe and well tolerated in children."( Contrast-enhanced sonography of malignant pediatric abdominal and pelvic solid tumors: preliminary safety and feasibility data.
Alpert, BS; Furman, WL; Hoffer, FA; Kaste, SC; Khan, RB; Li, C; McCarville, MB; Walton, RC; Xiong, X, 2012
)
0.66
" We evaluated these patients for serious adverse events (respiratory decompensation, hypotension, syncope, convulsions, arrhythmias, anaphylactic reactions, or death) occurring within 24 h of EC administration."( Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study.
Ahuja, A; Chaudhry, FA; Chaudhry, FF; De Benedetti Zunino, M; Henry, SA; Romero, J; Sareen, N; Sherrid, MV; Suma, V; Suryadevara, RS; Wever-Pinzon, O, 2012
)
0.38
"The use of the EC agent Definity is safe in hospitalized patients with PHT."( Safety of echocardiographic contrast in hospitalized patients with pulmonary hypertension: a multi-center study.
Ahuja, A; Chaudhry, FA; Chaudhry, FF; De Benedetti Zunino, M; Henry, SA; Romero, J; Sareen, N; Sherrid, MV; Suma, V; Suryadevara, RS; Wever-Pinzon, O, 2012
)
0.38
" This prospective, open-label, nonrandomized, multicenter, phase 4 surveillance registry study was conducted at 15 clinical sites in the United States and was designed to assess the risk for adverse cardiopulmonary events occurring during or within the initial 30 min after Definity administration in routine clinical practice."( CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.
Ahmad, M; Bhat, G; Hibberd, MG; Main, ML; Schmitz, S; Villanueva, F; Weiss, RJ, 2012
)
0.38
" Patients were assessed for adverse events at 30 min after Definity administration and then contacted by telephone at 24 ± 4 hours to record any subsequent adverse events."( CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.
Ahmad, M; Bhat, G; Hibberd, MG; Main, ML; Schmitz, S; Villanueva, F; Weiss, RJ, 2012
)
0.38
" No deaths, serious adverse events, or other significant adverse events occurred during this study."( CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.
Ahmad, M; Bhat, G; Hibberd, MG; Main, ML; Schmitz, S; Villanueva, F; Weiss, RJ, 2012
)
0.38
" However, there have been numerous safety notices issued by regulatory authorities regarding rare but potentially serious adverse reactions (AR)."( The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort.
Burstow, D; Call, T; Forshaw, A; Luis, SA; Pascoe, R; Platts, DG; Roper, D, 2013
)
0.7
"CEE is a safe investigation in a broad range of indications and clinical scenarios."( The safety profile of perflutren microsphere contrast echocardiography during rest and stress imaging: results from an Australian multicentre cohort.
Burstow, D; Call, T; Forshaw, A; Luis, SA; Pascoe, R; Platts, DG; Roper, D, 2013
)
0.7
" Sclerotomies appear to be safe and relatively easy to perform, without compromising the advantages of sutureless surgery."( Safety of 20-gauge transconjunctival sutureless vitrectomy.
Mangioris, G; Mendrinos, E; Papaefthymiou, I; Petropoulos, IK; Pournaras, CJ, 2013
)
0.39
" Large spontaneous reporting databases may help detect/refine signals of rare adverse events that elude other data sources/study designs."( Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.
Bangalore, S; Hanretta, KC; Hauben, M; Hung, EY; Snow, V, 2015
)
0.82
"We analyzed information from the US Food and Drug Administration Adverse Event Reporting System using a disproportionality analysis."( Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.
Bangalore, S; Hanretta, KC; Hauben, M; Hung, EY; Snow, V, 2015
)
0.82
"Our combined signal detection/evaluation analysis did not identify SDRs of novel adverse events or major cardiovascular events associated with perflutren ultrasound contrast agents."( Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.
Bangalore, S; Hanretta, KC; Hauben, M; Hung, EY; Snow, V, 2015
)
1.02
" In addition, we will discuss the confounding role of pseudocomplication in attribution of adverse events during diagnostic testing, the current status of the ECA Black Box Warning, and recommended safety precautions during ECA administration."( Safety With Echocardiographic Contrast Agents.
Main, ML; Muskula, PR, 2017
)
0.46
"Ultrasound enhancing agents (UEAs) are often utilized to enhance ultrasound image quality; however, concerns about adverse reactions have limited their use."( Safety profile of ultrasound enhancing agents in echocardiography.
Gibbons, P; Heitner, SB; Khan, AM; Kumar, S; Peterson, A; Purtell, C, 2019
)
0.51
"Over a 15-month period, patients receiving three different FDA-approved UEAs at our center were prospectively evaluated for clinically significant adverse events (AEs)."( Safety profile of ultrasound enhancing agents in echocardiography.
Gibbons, P; Heitner, SB; Khan, AM; Kumar, S; Peterson, A; Purtell, C, 2019
)
0.51
" This technique appears to be a safe and effective technique for faster resolution of corneal edema post hydrops."( Evaluating the safety and efficacy of compression sutures with intracameral perfluoropropane (C3F8) in the management of acute corneal hydrops.
D'Souza, S; James, E; Kundu, G; Shetty, R; Vohra, V, 2021
)
0.62

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic studies were then performed in vivo in a subcutaneous human colorectal adenocarcinoma (LS174T) in mice."( Acoustic characterization and pharmacokinetic analyses of new nanobubble ultrasound contrast agents.
Exner, AA; Guenette, G; Kamiyama, N; Krupka, TM; Rognin, NG; Sanders, C; Solorio, L; Wu, H; Yoshiara, H, 2013
)
0.39

Compound-Compound Interactions

ExcerptReferenceRelevance
"To assess prospectively the comeal endothelial damage associated with pars plana vitrectomy combined with lensectomy and gas tamponade."( Corneal endothelial cell loss in eyes undergoing lensectomy with and without anterior lens capsule removal combined with pars plana vitrectomy and gas tamponade.
Mitamura, Y; Yamamoto, S; Yamazaki, S, 2000
)
0.31
"The corneal endothelium was examined with a specular microscope preoperatively and 6 months postoperatively in 42 eyes that underwent pars plana vitrectomy combined with total lensectomy and gas tamponade with SF6 (19 eyes) or C3F8 (23 eyes), and in 12 control eyes that underwent vitrectomy combined with anterior capsule-preserved lensectomy and gas tamponade."( Corneal endothelial cell loss in eyes undergoing lensectomy with and without anterior lens capsule removal combined with pars plana vitrectomy and gas tamponade.
Mitamura, Y; Yamamoto, S; Yamazaki, S, 2000
)
0.31
"These results suggest that ophthalmic surgeons must try to preserve the lens capsule as much as possible in vitrectomy combined with lensectomy and long-acting gas tamponade in order to prevent corneal endothelial damage."( Corneal endothelial cell loss in eyes undergoing lensectomy with and without anterior lens capsule removal combined with pars plana vitrectomy and gas tamponade.
Mitamura, Y; Yamamoto, S; Yamazaki, S, 2000
)
0.31
"We have developed a method to use low-intensity focused ultrasound pulses combined with an ultrasound contrast agent to produce temporary blood-brain barrier disruption (BBBD)."( Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study.
Hynynen, K; McDannold, N; Vykhodtseva, N, 2007
)
0.34
"Numerous animal studies have demonstrated that ultrasound bursts combined with a microbubble-based ultrasound contrast agent can temporarily disrupt the blood-brain barrier (BBB) with little or no other apparent effects to the brain."( Blood-brain barrier disruption and vascular damage induced by ultrasound bursts combined with microbubbles can be influenced by choice of anesthesia protocol.
McDannold, N; Vykhodtseva, N; Zhang, Y, 2011
)
0.37
"To detect the early effects of pars plana vitrectomy (PPV) combined with intravitreal gas tamponade on corneal biomechanics and compare these effects of sulfur hexafluoride (SF6) and perfluropropane (C3F8)."( Early effects of pars plana vitrectomy combined with intravitreal gas tamponade on corneal biomechanics.
Elgin, U; Ozdal, P; Ozturk, F; Sen, E; Teke, MY, 2013
)
0.39
"To study the anatomical outcome of rhegmatogenous retinal detachment combined with choroidal detachment after pars plana vitrectomy with periocular/intravitreal injection of steroids."( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment.
Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014
)
0.4
"Seventy-seven eyes that have rhegmatogenous retinal detachment combined with choroidal detachment were treated by pars plana vitrectomy with oral prednisolone (Group A) or periocular/intravitreal injection of steroids (Group B) and then divided into 5 subgroups according to different intraocular tamponade agents; Group A1: oral steroids and silicone oil, Group A2: oral steroids and C(3)F(8), Group B1: periocular/intravitreal steroid injections and silicone oil, Group B2: periocular steroid injection and silicone oil, and Group B3: periocular steroid injection and C(3)F(8)."( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment.
Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014
)
0.4
"For the treatment of rhegmatogenous retinal detachment combined with choroidal detachment, pars plana vitrectomy with periocular/intravitreal corticosteroids was comparable in reattachment rate to pars plana vitrectomy with systemic steroids, suggesting an acceptable alternative for patients with this condition who cannot tolerate systemic steroids."( Vitrectomy combined with periocular/intravitreal injection of steroids for rhegmatogenous retinal detachment associated with choroidal detachment.
Bi, C; Chen, F; Wang, H; Wang, N; Wei, Y; Yang, X; Zu, Z, 2014
)
0.4
"To evaluate the long-term clinical efficacy and safety of gas tamponade combined with laser photocoagulation for optic disc pit maculopathy."( Gas tamponade combined with laser photocoagulation therapy for congenital optic disc pit maculopathy.
Atik, A; Ding, X; Hu, Y; Lei, L; Li, T; Ma, W; Tang, S; Zhu, X, 2015
)
0.42
"Seven consecutive patients with unilateral maculopathy associated with optic disc pit and one patient with bilateral optic disc pit maculopathy were given octafluoropropane (C3F8) tamponade combined with focal laser photocoagulation treatment."( Gas tamponade combined with laser photocoagulation therapy for congenital optic disc pit maculopathy.
Atik, A; Ding, X; Hu, Y; Lei, L; Li, T; Ma, W; Tang, S; Zhu, X, 2015
)
0.42
"Although repeated treatment was needed in some patients, C3F8 tamponade combined with laser photocoagulation is still a simple, effective, minimally invasive, and economic therapy for optic disc pit maculopathy."( Gas tamponade combined with laser photocoagulation therapy for congenital optic disc pit maculopathy.
Atik, A; Ding, X; Hu, Y; Lei, L; Li, T; Ma, W; Tang, S; Zhu, X, 2015
)
0.42
" Recombinant tissue plasminogen activator (rt-PA) and rt-PA-loaded echogenic liposomes that entrain octafluoropropane microbubbles (OFP t-ELIP) were used in combination with highly shocked histotripsy pulses."( Efficacy of histotripsy combined with rt-PA in vitro.
Bader, KB; Haworth, KJ; Holland, CK; Maxwell, AD; McPherson, DD; Peng, T; Shekhar, H, 2016
)
0.43

Dosage Studied

ExcerptRelevanceReference
" Varying the infusion rate or trigger interval was less important than the overall dosage during scanning."( The influence of agent delivery mode on cardiomyocyte injury induced by myocardial contrast echocardiography in rats.
Armstrong, WF; Dou, C; Miller, DL, 2005
)
0.33
" We concluded that BBBD is possible using Definity at the dosage of contrast agent and the acoustic parameters tested in this study."( Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study.
Hynynen, K; McDannold, N; Vykhodtseva, N, 2007
)
0.34
" In this study we investigate the dose-response relationship of ultrasound contrast agent for a minimal exposure power Doppler technique (minexPD) in a murine melanoma model."( Dose-response relationship of ultrasound contrast agent in an in vivo murine melanoma model.
Lee, WM; Schultz, S; Sehgal, CM; Seiler, GS; Ziemer, LS, 2007
)
0.34
" Multi-pulse, phase inversion, low mechanical index imaging was used (left ventricular opacification), combined with bolus dosing of a perflutren microsphere (Definity)."( Direct visualization of septal perforator coronary arterial blood flow during perflutren microsphere contrast echocardiography.
Boga, T; Burstow, D; Hamilton-Craig, C; Platts, D; West, C, 2009
)
0.78
" Permutations of input to the neural network data classification scheme revealed that tumor perfusion data within 3 days of bevacizumab dosing was sufficient to minimize the prediction error to 10%, whereas measurements of physical tumor size alone did not appear adequate to assess the therapeutic response."( Determination of breast cancer response to bevacizumab therapy using contrast-enhanced ultrasound and artificial neural networks.
Belt, L; Hoyt, K; Lockhart, ME; Robbin, ML; Umphrey, H; Warram, JM; Zinn, KR, 2010
)
0.36
"The administration of Definity at the approved dosage does not change pulmonary or systemic hemodynamics in control patients or those with mild to moderate pulmonary hypertension."( The effect of Definity on systemic and pulmonary hemodynamics in patients.
Ahmad, M; Angeli, S; Bernstein, JA; Klein, A; Lang, RM; Lee, LV; Main, ML; Mikati, I; Panetta, C; Wei, K, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
fluorocarbonCompounds consisting wholly of fluorine and carbon.
fluoroalkaneA haloalkane that is an alkane in which at least one hydrogen atom has been replaced by a fluorine atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID416913Convulsant activity in Sprague-Dawley rat assessed as partial pressure in atmosphere at which convulsion takes place2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Prediction of convulsant activity of gases and vapors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,081)

TimeframeStudies, This Drug (%)All Drugs %
pre-199040 (3.70)18.7374
1990's145 (13.41)18.2507
2000's378 (34.97)29.6817
2010's469 (43.39)24.3611
2020's49 (4.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 53.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index53.92 (24.57)
Research Supply Index7.15 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index90.25 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (53.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials90 (7.65%)5.53%
Reviews44 (3.74%)6.00%
Case Studies217 (18.44%)4.05%
Observational11 (0.93%)0.25%
Other815 (69.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]